Growth Hormone Treatment in Short Children with ß-Thalassaemia Major
| Autor: | F. Harsoulis, M. Athanasiou-Metaxa, G. Katzos, E. Papakostantinou-Athanasiadou |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Endocrinology Liver Function Tests Internal medicine Humans Insulin Medicine Insulin-Like Growth Factor I Child Growth Disorders Thalassaemia major business.industry Human growth hormone beta-Thalassemia Final height Transfusion Reaction Bone age Chronological age Body Height Growth hormone treatment Thyroxine Growth Hormone Pediatrics Perinatology and Child Health Gh treatment Bone maturation business |
| Zdroj: | Journal of Pediatric Endocrinology and Metabolism. 13 |
| ISSN: | 2191-0251 0334-018X |
| DOI: | 10.1515/jpem.2000.13.2.163 |
| Popis: | The effect of one year recombinant human growth hormone (rhGH) treatment on growth rate and bone age was studied in ten short prepubertal children with beta-thalassemia major (age range 7.10-12.03 yr) with normal GH response to provocative stimuli. rhGH was given subcutaneously every day in a dose of 28 IU/m2/week. In the 10 children who completed 12 months of treatment the growth velocity increased from 4.22+/-0.81 cm/yr (-1.38+/-0.80 SDS for CA) to 7.61+/-1.16 cm/yr (+2.27+/-1.64 SDS for CA). IGF-I was low before treatment, 138.3 +/-38.9 ng/ml, and rose significantly to 232.2+/-122.1, 243.2+/-98.4 and 227.5+/-86.2 at 3, 6 and 12 months post-treatment, respectively (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|